Fosfomycin sodium (Standard)
Based on 1 Customer Validation
Fosfomycin sodium (Standard) (MK-0955 sodium (Standard)) is the analytical standard of Fosfomycin sodium (HY-W016420). This product is intended for research and analytical applications. Fosfomycin (MK-0955) sodium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin sodium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria.
For research use only. We do not sell to patients.
- Purity : 99.24%
- CAS No.: 26016-99-9
- Formula: C3H5Na2O4P
- Molecular Weight:182.02
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
-
HY-W016420
Fosfomycin sodiumAntibiotic -
HY-B0472
Streptomycin sulfateBacterial Inhibitor -
HY-15463
ImatinibTyrosine Kinases Inhibitor -
HY-B1350A
Fusidic acid sodium saltBacteriostatic Antibiotic -
HY-15463R
Imatinib (Standard)Tyrosine Kinases Inhibitor -
HY-B0472R
Streptomycin sulfate (Standard)Bacterial Inhibitor -
HY-B1350AR
Fusidic acid sodium salt (Standard)Bacteriostatic Antibiotic
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 26016-99-9
-
Appearance Solid
-
Molecular Weight 182.02
-
Formula C3H5Na2O4P
-
Color White to off-white
-
SMILES
C[C@@H]1O[C@@H]1P(O[Na])(O[Na])=O
-
Synonyms
MK-0955 sodium (Standard)
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Falagas ME, et al. Fosfomycin. Clin Microbiol Rev. 2016 Apr. 29(2):321-47. [Content Brief]
[2]. Dijkmans AC, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel). 2017 Oct 31. 6(4):24. [Content Brief]
[3]. Inouye S, et al. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J Pharmacobiodyn. 1982 Sep. 5(9):659-69. [Content Brief]
[4]. Inouye S, et al. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. J Pharmacobiodyn. 1982 Dec. 5(12):941-50. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Fosfomycin sodium (Standard) Related Classifications
HY-W016420R Related Classifications
Powered by Bioz
Keywords
- Fosfomycin sodium (Standard)
- 26016-99-9
- MK-0955 sodium (Standard)
- Reference Standards
- Bacterial
- Antibiotic
- sepsis
- pharmacokinetic
- safety
- multidrug-resistant
- MDR
- extensively drug-resistant
- XDR
- pan-drug-resistant
- PDR,antimicrobial activity
- antibiotic
- dibekacin
- nephrotoxicity
- drug elimination
- renal lysosome
- dehydrated mouse
- Inhibitor
- inhibitor
- inhibit